AMBEV S.A. (3Q25) Investor Summary (Form 6-K/A)
Financial & Performance Highlights (Organic/Normalized vs. 3Q24):
- EPS Growth: +7%.
- Revenue: Net revenue grew, with resilient Net Revenue per hectoliter (NR/hl) up 7%.
- EBITDA: Growth achieved with margin expansion across most Business Units (BUs).
- Normalized Net Income: Grew +7%.
Strategic Execution & Volume:
- Total volume declined 100% due to industry softness (e.g., consumer pressure, colder weather).
- Ambev gained market share across all relevant segments.
- Premium & Super Premium v